Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Corticosteroids for Severe Acute GVHD
NCT07509749Phase 2Recruiting
- Sponsor
- Daihong Liu
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Daihong Liu. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07509749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509749.